Tower Research Capital (TRC)’s AbCellera Biologics ABCL Stock Holding History
Bought
Maintained
Sold
Other funds holding ABCL
BBA
Tower Research Capital (TRC)'s ABCL Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its AbCellera Biologics (ABCL) stake by 4,456% in Q3 2026, buying an estimated $465K and bringing the position to 50,165 shares worth $732K. The position accounts for 0.01% of the portfolio, ranked #1295.
Tower Research Capital (TRC) first reported a position in ABCL in Q4 2020 and has held it in 24 quarters since. 164 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.
- Tower Research Capital (TRC) held 50,165 shares of AbCellera Biologics worth $732K as of Q3 2026.
- Tower Research Capital (TRC) bought 49,064 AbCellera Biologics shares in Q3 2026, an estimated $465K.
- AbCellera Biologics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #1295 holding.
- Tower Research Capital (TRC) first reported a position in AbCellera Biologics in Q4 2020 and has held it in 24 quarters since.
- 164 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.